Patents by Inventor Shingo Yamamoto
Shingo Yamamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200191209Abstract: Provided is a clutch friction plate and a clutch device configured so that stiction torque can be reduced and each of in gear, shift feeling, and neutral find can be smoothly performed. A clutch device (100) includes clutch friction plates (101). In the clutch friction plate (101), multiple small-piece-shaped friction members (103) are radially bonded to surfaces of a core bar (102) formed in a flat-plate annular shape through an oil groove (105). Each friction member (103) includes an outer side (104a) facing an outer edge portion of the core bar (102) and an inner side (104b) facing an inner edge portion of the core bar (102) and extending parallel to the outer side (104a), and is formed in a rectangular shape.Type: ApplicationFiled: March 7, 2018Publication date: June 18, 2020Inventors: Shingo YAMAMOTO, Yoshihiko OZAWA, Kazuma MATSUSHITA, Hiroki HARA, Hiroyuki IJIMA
-
Publication number: 20200048256Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: ApplicationFiled: October 16, 2019Publication date: February 13, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
-
Publication number: 20200000810Abstract: The present invention relates to a Brk inhibitory compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug of any of these.Type: ApplicationFiled: December 20, 2017Publication date: January 2, 2020Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Masakuni KURONO, Atsushi YOSHIDA, Shingo HOTTA
-
Patent number: 10487085Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: GrantFiled: February 7, 2019Date of Patent: November 26, 2019Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Publication number: 20190315756Abstract: The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.Type: ApplicationFiled: June 27, 2019Publication date: October 17, 2019Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Hiroshi TOKURA, Masakuni KURONO, Yoshinori NOMURA, Shingo HOTTA
-
Publication number: 20190315748Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: ApplicationFiled: June 25, 2019Publication date: October 17, 2019Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
-
Patent number: 10377759Abstract: The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.Type: GrantFiled: June 21, 2016Date of Patent: August 13, 2019Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Hiroshi Tokura, Masakuni Kurono, Yoshinori Nomura, Shingo Hotta
-
Patent number: 10370377Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: GrantFiled: April 27, 2018Date of Patent: August 6, 2019Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Patent number: 10314844Abstract: Inhibitors for Bruton's Tyrosine Kinase (BTK) are disclosed as are compositions thereof, methods for their preparation, and methods for their use.Type: GrantFiled: February 23, 2018Date of Patent: June 11, 2019Assignees: GILEAD SCIENCES, INC., ONO PHARMACEUTICAL CO., LTD.Inventors: Seung H. Lee, Shingo Yamamoto
-
Publication number: 20190169192Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: ApplicationFiled: February 7, 2019Publication date: June 6, 2019Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
-
Patent number: 10233185Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: GrantFiled: February 13, 2018Date of Patent: March 19, 2019Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Publication number: 20180244675Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: ApplicationFiled: April 27, 2018Publication date: August 30, 2018Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
-
Publication number: 20180243311Abstract: Inhibitors for Bruton's Tyrosine Kinase (BTK) are disclosed as are compositions thereof, methods for their preparation, and methods for their use.Type: ApplicationFiled: February 23, 2018Publication date: August 30, 2018Inventors: Seung H. Lee, Shingo Yamamoto
-
Publication number: 20180186800Abstract: The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.Type: ApplicationFiled: June 21, 2016Publication date: July 5, 2018Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Hiroshi TOKURA, Masakuni KURONO, Yoshinori NOMURA, Shingo HOTTA
-
Publication number: 20180170933Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: ApplicationFiled: February 13, 2018Publication date: June 21, 2018Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
-
Patent number: 9981966Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: GrantFiled: July 19, 2017Date of Patent: May 29, 2018Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Patent number: 9926322Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: GrantFiled: July 13, 2017Date of Patent: March 27, 2018Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Patent number: 9896453Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.Type: GrantFiled: May 19, 2016Date of Patent: February 20, 2018Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Patent number: 9879013Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: GrantFiled: December 9, 2014Date of Patent: January 30, 2018Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo Yamamoto, Toshio Yoshizawa
-
Publication number: 20170313705Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.Type: ApplicationFiled: July 13, 2017Publication date: November 2, 2017Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA